Strategic Investments Overview
OPKO’s growth strategy includes investing in early-stage companies that we perceive to have valuable proprietary technology and significant potential to create value for OPKO as a shareholder. Some of our most recent investments include:
BioZone Pharmaceuticals, Inc. (Englewood Cliffs, NJ) is a publicly-traded company engaged in the manufacture and sale of several pharmaceutical and cosmetic products for a variety of conditions. In addition to owning convertible promissory notes from Biozone, OPKO holds a world-wide license for the development and commercialization of products utilizing Biozone’s proprietary drug delivery technology, including QuSomes, exclusively for OPKO in the field of ophthalmology and non-exclusive for all other therapeutic fields, subject in each case to certain excluded products.
ChromaDex Corporation (Irvine, CA), a publicly traded entity, is a leading provider of proprietary ingredients and products for the dietary supplement, nutraceutical, food and beverage, functional food, pharmaceutical, and cosmetic markets. In 2011, ChromaDex launched BluScience™, a line of dietary supplements based on pterostilbene, an antioxidant compound found in blueberries. This product line is currently marketed nationwide through GNC and Walgreens. In addition to stock investments in Chromadex, OPKO also holds distribution rights to certain ChromaDex products in Latin America.
Cocrystal Discovery (Bothell, WA) is a privately held biopharmaceutical company focused on the discovery and development of novel small molecule antiviral therapeutics tailored for the treatment of serious and chronic viral diseases, It is currently developing oral, small molecule, antiviral therapeutics for Hepatitis C and influenza. In 2011, Cocrystal and Teva Pharmaceutical Industries, Ltd. signed a Research Collaboration Agreement, an Exclusive License Option Agreement, and a Share Purchase Agreement for Teva’s investment in Cocrystal, regarding research on the development of a broad-spectrum antiviral drug targeting the Hepatitis C virus.
Fabrus, Inc. (San Diego, CA) is a privately-held early stage biotechnology company with next generation therapeutic antibody drug discovery and development capabilities that is using its proprietary antibody screening and engineering approach to discover promising lead compounds against several important oncology targets.
Neovasc, Inc. (Vancouver BC, Canada) is a publicly-traded company recently named the 2012 Medical Device Company of the Year by LifeSciences British Columbia. Featuring a line of products that are approved for sale and distribution worldwide, Neovasc develops, manufactures, and markets innovative vascular devices such as the Neovasc Reducer™ for refractory angina and PeriPatch™ surgical tissue used in cardiac reconstruction.
Sorrento Therapeutics, Inc. (San Diego, CA) is a publicly-traded biopharmaceutical company focused on applying its proprietary technology platform for the discovery and development of human therapeutic antibodies for the treatment of a variety of disease conditions, including cancer, inflammation, metabolic disease and infectious disease.
TESARO (Waltham, MA) is a publicly traded oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by developing and providing safer and more effective therapeutic and supportive care products, including Rolapitant, an NK-1 antagonist licensed from OPKO and indicated for chemotherapy-induced nausea and vomiting (CINV).